Who Buys Etoposide from India — 598 Importers Behind a $10.8M Market

The importation of Etoposide from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like EVERSANA LIFE SCIENCES SERVICES, LLC and AMERISOURCE HEALTH SERVICES in the United States fall into this category. They procure large volumes to supply hospitals, clinics, and pharmacies, often engaging in long-term contracts to ensure consistent supply.

• Hospital Groups: Organizations such as FRESENIUS KABI DEUTSCHLAND GMBH in Germany represent hospital groups. They purchase Etoposide directly for patient treatment, focusing on quality and timely delivery to meet patient needs.

• Government Procurement Agencies: While not explicitly listed among the top buyers, entities like UNICEF and The Global Fund often engage in large-scale procurement through tenders to supply public health facilities, emphasizing cost-effectiveness and broad accessibility.

• Re-exporters: Companies like BROCACEF NL : HUB in the Netherlands may act as re-exporters, importing Etoposide for redistribution to other markets, leveraging strategic geographic positions and trade agreements.

• Contract Manufacturers: Entities such as CSP MYLAN IRELAND LIMITED in France might procure Etoposide as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to stringent quality standards and regulatory compliance.

Each segment's purchasing patterns are influenced by factors like regulatory requirements, market demand, and supply chain logistics, necessitating tailored strategies for engagement and supply chain management.

Understanding the import regulations for Etoposide in the top importing countries is crucial:

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires submission of an Abbreviated New Drug Application (ANDA) for generic drugs, including Etoposide.
• Estimated Timeline: Typically 10 months for standard review.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049045 are generally duty-free.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires a Marketing Authorization Application (MAA) submission.
• Estimated Timeline: Approximately 210 days for assessment.
• Import Tariff/Duty: As an EU member, imports from India may be subject to a 0% duty under the Generalized System of Preferences (GSP).

• France:
• Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).
• Import Registration Process: Submission of a Marketing Authorization Application (MAA) is required.
• Estimated Timeline: Around 210 days for evaluation.
• Import Tariff/Duty: Under the EU's GSP, imports from India may benefit from reduced or zero tariffs.

• Colombia:
• Regulatory Authority: National Institute for Food and Drug Surveillance (INVIMA).
• Import Registration Process: Requires a Sanitary Registration, including dossier submission and local testing.
• Estimated Timeline: Approximately 6 to 12 months.
• Import Tariff/Duty: Pharmaceutical products may be subject to a 5% import duty.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Submission of a Marketing Authorization Application (MAA) is necessary.
• Estimated Timeline: Around 210 days for processing.
• Import Tariff/Duty: As part of the EU, Germany applies the GSP, potentially allowing for reduced or zero tariffs on imports from India.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Etoposide is driven by several factors:

• Disease Prevalence: Etoposide is primarily used in the treatment of various cancers, including lung cancer and testicular cancer. The global incidence of these cancers continues to rise, necessitating increased availability of effective chemotherapeutic agents.

• Government Healthcare Programs: Many countries have national cancer control programs that include Etoposide in their treatment protocols, ensuring its procurement and distribution through public health systems.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines, including Etoposide, as governments strive to provide comprehensive cancer care.

• WHO Essential Medicines List Procurement: Etoposide's inclusion in the WHO Model List of Essential Medicines facilitates its procurement by international organizations and national health systems, ensuring its availability in resource-limited settings.

• Tender-Based Purchasing: Many health systems and international organizations utilize tender processes to procure medicines like Etoposide, promoting competitive pricing and ensuring supply chain efficiency.

With 598 buyers across 122 countries, the global market for Etoposide is robust, presenting significant opportunities for suppliers to meet the growing demand driven by these factors.

The importation of Etoposide from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like EVERSANA LIFE SCIENCES SERVICES, LLC and AMERISOURCE HEALTH SERVICES in the United States fall into this category. They procure large volumes to supply hospitals, clinics, and pharmacies, often engaging in long-term contracts to ensure consistent supply.

• Hospital Groups: Organizations such as FRESENIUS KABI DEUTSCHLAND GMBH in Germany represent hospital groups. They purchase Etoposide directly for patient treatment, focusing on quality and timely delivery to meet patient needs.

• Government Procurement Agencies: While not explicitly listed among the top buyers, entities like UNICEF and The Global Fund often engage in large-scale procurement through tenders to supply public health facilities, emphasizing cost-effectiveness and broad accessibility.

• Re-exporters: Companies like BROCACEF NL : HUB in the Netherlands may act as re-exporters, importing Etoposide for redistribution to other markets, leveraging strategic geographic positions and trade agreements.

• Contract Manufacturers: Entities such as CSP MYLAN IRELAND LIMITED in France might procure Etoposide as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to stringent quality standards and regulatory compliance.

Each segment's purchasing patterns are influenced by factors like regulatory requirements, market demand, and supply chain logistics, necessitating tailored strategies for engagement and supply chain management.

Understanding the import regulations for Etoposide in the top importing countries is crucial:

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires submission of an Abbreviated New Drug Application (ANDA) for generic drugs, including Etoposide.
• Estimated Timeline: Typically 10 months for standard review.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049045 are generally duty-free.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires a Marketing Authorization Application (MAA) submission.
• Estimated Timeline: Approximately 210 days for assessment.
• Import Tariff/Duty: As an EU member, imports from India may be subject to a 0% duty under the Generalized System of Preferences (GSP).

• France:
• Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).
• Import Registration Process: Submission of a Marketing Authorization Application (MAA) is required.
• Estimated Timeline: Around 210 days for evaluation.
• Import Tariff/Duty: Under the EU's GSP, imports from India may benefit from reduced or zero tariffs.

• Colombia:
• Regulatory Authority: National Institute for Food and Drug Surveillance (INVIMA).
• Import Registration Process: Requires a Sanitary Registration, including dossier submission and local testing.
• Estimated Timeline: Approximately 6 to 12 months.
• Import Tariff/Duty: Pharmaceutical products may be subject to a 5% import duty.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Submission of a Marketing Authorization Application (MAA) is necessary.
• Estimated Timeline: Around 210 days for processing.
• Import Tariff/Duty: As part of the EU, Germany applies the GSP, potentially allowing for reduced or zero tariffs on imports from India.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Etoposide is driven by several factors:

• Disease Prevalence: Etoposide is primarily used in the treatment of various cancers, including lung cancer and testicular cancer. The global incidence of these cancers continues to rise, necessitating increased availability of effective chemotherapeutic agents.

• Government Healthcare Programs: Many countries have national cancer control programs that include Etoposide in their treatment protocols, ensuring its procurement and distribution through public health systems.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines, including Etoposide, as governments strive to provide comprehensive cancer care.

• WHO Essential Medicines List Procurement: Etoposide's inclusion in the WHO Model List of Essential Medicines facilitates its procurement by international organizations and national health systems, ensuring its availability in resource-limited settings.

• Tender-Based Purchasing: Many health systems and international organizations utilize tender processes to procure medicines like Etoposide, promoting competitive pricing and ensuring supply chain efficiency.

With 598 buyers across 122 countries, the global market for Etoposide is robust, presenting significant opportunities for suppliers to meet the growing demand driven by these factors.